[1] GOLDIN A,BECKMAN J A,SCHMIDT A M,et al.Advanced glycation end products: sparking the development of diabetic vascular injury[J].Circulation,2006,114(6):597-605.
[2] SANTILLI F,VAZZANA N,BUCCIARELLI L G,et al.Soluble forms of RAGE in human diseases: clinical and therapeutical implications[J].Curr Med Chem,2009,16(8):940-952.
[3] BARI Investigators.The final 10-year follow-up results from the BARI randomized trial[J].J Am Coll Cardiol,2007,49(15):1600-1606.
[4] ZHANG L,POSTINA R,WANG Y.Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease[J].Cell Mol Life Sci,2009,66(24):3923-3935.
[5] RAUCCI A,CUGUSI S,ANTONELLI A,et al.A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase A Disintegrin And Metalloprotease 10 (ADAM10)[J].FASEB J,2008,22(10):3716-3727.
[6] ZHANG L,BUKULIN M,KOJRO E,et al.Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases[J].J Biol Chem,2008,283(51):35507-35516.
[7] PARKIN E,HARRIS B.A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10[J].J Neuro-chem,2009,108(6):1464-1479.
[8] GALICHET A,WEIBEL M,HEIZMANN C W.Calcium-regulated intramembrane proteolysis of the RAGE receptor[J].Biochem Biophys Res Commun,2008,370(1):1-5.
[9] HUDSON B I,CARTER A M,HARJA E,et al.Identification,classification,and expression of RAGE gene splice variants[J].FASEB J,2008,22(5):157-158.
[10] JANG Y,KIM J Y,KANG S M,et al.Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans[J].Metabolism,2007,56(2):199-205.
[11] HOFMANN M A,DRURY S,HUDSON B I,et al.RAGE and arthritis:the G82S polymorphism amplifies the inflammatory response[J].Genes Immun,2002,3(3):123-135.
[12] CATALANO M,CORTELAZZO A,SANTI R,et al.The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease[J].Clin Biochem,2008,41(12):981-985.
[13] KALOUSOVA M,GERMANOVA A,JACHYMOVA M,et al.A419C (E111A) polymorphism of the glyoxalase I gene and vascular complications in chronic hemodialysis patients[J].Ann N Y Acad Sci,2008,1126:268-271.
[14] WITTKOWSKI H,HIRONO K,ICHIDA F,et al.Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12[J].Arthritis Rheum,2007,56(12):4174-4181.
[15] PARK L,RAMAN K G,LEE K J,et al.Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end- products[J].Nat Med,1998,4(9):1025-1031.
[16] BUCCIARELLI L G,WENDT T,QU W,et al.RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice[J].Circulation,2002,106(22):2827-2835.
[17] FALCONE C,EMANUELE E,D'ANGELO A,et al.Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men[J].Arterioscler Thromb Vasc Biol,2005,25(5):1032-1037.
[18] KOYAMA H,SHOJI T,YOKOYAMA H,et al.Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis[J].Arterioscler Thromb Vasc Biol,2005,25(12): 2587-2593.
[19] KATAKAMI N,MATSUHISA M,KANETO H,et al.Endogenous secretory receptor for advanced glycation end product levels are inversely associated with HbA1C in type 2 diabetic patients[J].Diabetes Care,2006,29(2):469.
[20] KATAKAMI N,MATSUHISA M,KANETO H,et al.Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type2 diabetic patients[J].Atherosclerosis,2007,190(1):22-23.
[21] KOYAMA H,SHOJI T,FUKUMOTO S,et al.Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease[J].Arterioscler Thromb Vasc Biol,2007,27(1):147-153.
[22] MONTANER J,PEREA-GAINZA M,DELGADO P,et al.Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers[J].Stroke,2008,39(8):2280-2287.
[23] GEROLDI D,FALCONE C,EMANUELE E,et al.Decreased plasma levels of soluble receptor for advanced glycation end products in patients with essential hypertension[J].J Hypertens,2005,23(9):1725.
[24] GERMANOVA A,KOUCKY M,HAJEK Z,et al.Soluble receptor for advanced glycation end products in physiological and pathological pregnancy[J].Clin Biochem,2010,43(4-5): 442-446.
[25] FORBES J M,THORPE S R,THALLAS-BONKE V,et al.Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy[J].J Am Soc Nephrol,2005,16(8):2363-2372.
[26] SANTILLI F,BUCCIARELLI L,NOTO D,et al.Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins[J].Free Radic Biol Med,2007,43(9):1255-1262.
[27] 智宏,任利群,马根山,等.冠心病合并代谢综合征者炎症因子水平与冠脉病变程度的研究[J].东南大学学报:医学版,2009,28(1):10-12.
[28] HOLMAN R R,PAUL S K,BETHEL M A,et al.10-year follow-up of intensive glucose control in type 2 diabetes[J].N Engl J Med,2008,359(15):1577-1589.
[29] DLUHY R G,McMAHON G T.Intensive glycemic control in the ACCORD and ADVANCE trials[J].N Engl J Med,2008,358(24):2630-2633.
[30] BASTA G,SIRONI A M,LAZZERINI G,et al.Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein[J].J Clin Endocrinol Metab,2006,91(11):4628-4634.
[31] DEVANGELIO E,SANTILLI F,FORMOSO G,et al.Soluble RAGE in type 2 diabetes:association with oxidative stress[J].Free Radic Biol Med,2007,43(4):511-518.
[32] SANTILLI F,VAZZANA N,BUCCIARELLI L G,et al.Soluble forms of RAGE in human diseases: clinical and therapeutical implications[J].Curr Med Chem,2009,16(8):940-952.
[33] TAN K C,CHOW W S,TSO A W,et al.Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes[J].Diabetologia,2007,50(9):1819-1825.
[34] HUDSON B I,WENDT T,BUCCIARELLI L G,et al.Diabetic vascular disease: it's all the RAGE[J].Antioxid Redox Signal,2005,7(11-12):1588-1600.
[35] GROSSIN N,WAUTIER M P,MEAS T,et al.Severity of diabetic microvascular complications is associated with a low soluble RAGE level[J].Diabetes Metab,2008,34(4):392-395.
[36] KOYAMA H,YAMAMOTO H,NISHIZAWA Y.RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases[J].Mol Med,2007,13(11-12):625-635.
[37] SEMBA R D,FERRUCCI L,FINK J C,et al.Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women[J].Am J Kidney Dis,2009,53(1):51-58.
[38] NIN J W,FERREIRA I,SCHALKWIJK C G,et al.Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes,and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study[J].Diabetologia,2009,52(4):705-714.
[39] KOYAMA H,SHOJI T,FUKUMOTO S,et al.Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease[J].Arterioscler Thromb Vasc Biol,2007,27(1):147-153.
[40] HUMPERT P M,PAPADOPOULOS G,SCHAEFER K,et al.sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes[J].Horm Metab Res,2007,39(12):899-902.
[41] CHEN X,WALKER D G,SCHMIDT A M,et al.RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease[J].Curr Mol Med,2007,7(8):735-742.
[42] EMANUELE E,D'ANGELO A,TOMAINO C,et al.Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia[J].Arch Neurol,2005,62(11):1734-1736.
[43] GHIDONI R,BENUSSI L,GLIONNA M,et al.Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment[J].J Neural Transm,2008,115(7):1047-1050.
[44] STERNBERG Z,WEINSTOCK-GUTTMAN B,HOJNACKI D,et al.Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity[J].Mult Scler,2008,14(6):759-763.
[45] ILZECKA J.Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis[J].Acta Neurol Scand,2008,120(2):119-122.
[46] LEACH S T,YANG Z,MESSINA I,et al.Serum and mucosal S100 proteins,calprotectin (S100A8/S100A9) and S100A12,are elevated at diagnosis in children with inflammatory bowel disease[J].Scand J Gastroenterol,2007,42(11):1321-1331.
[47] De LEEUW K,SANDERS J S,STEGEMAN C,et al.Accelerated atherosclerosis in patients with Wegener's granulomatosis[J].Ann Rheum Dis,2005,64(5):753-759.
[48] MANZI S,MEILAHN E N,RAIRIE J E,et al.Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study[J].Am J Epidemiol,1997,145(5):408-415.
[49] NORATA G D,GARLASCHELLI K,GRIGORE L,et al.Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population[J].Nutr Metab Cardiovasc Dis,2008,19(2):129-134.
[50] CATALANO M,CORTELAZZO A,SANTI R,et al.The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (receptor for advanced glycation end products) and the presence of peripheral arterial disease[J].Clin Biochem,2008,41(12):981-985.
[51] LOGSDON C D,FUENTES M K,HUANG E H,et al.RAGE and RAGE ligands in cancer[J].Curr Mol Med,2007,7(8):777-789.
[52] ABE R,YAMAGISHI S.AGE-RAGE system and carcinogenesis[J].Curr Pharm Des,2008,14(10):940-945.
[53] TESAROVA P,KALOUSOVA M,JACHYMOVA M,et al.Receptor for advanced glycation end products (RAGE)—soluble form (sRAGE) and gene polymorphisms in patients with breast cancer[J].Cancer Invest,2007,25(8):720-725.
[54] KRECHLER T,JACHYMOVA M,MESTEK O,et al.Soluble receptor for advanced glycation end-products(sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer[J].Clin Biochem,2010,43(10 -11): 882-886.
[55] GU H,YANG L,SUN Q,et al.Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population[J].Clin Cancer Res,2008,14(11):3627-3632. |
